Skip to main content

Remote Job Finders (RJF)

With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’

Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the pressure and cleared the way for some early-stage bets, CEO Chris Viehbacher said Wednesday.

Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings

Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key upcoming readouts, including for LAG3 candidate fianlimab in metastatic melanoma.

Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly

Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to treat severe swelling episodes caused by the rare genetic disorder hereditary angioedema.

Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions

Sanofi and Novartis kick off the heart of earnings season; Lilly strikes its fourth pact in as many weeks; Regeneron earns landmark approval for a gene therapy for a type of genetic deafness, and also strikes a White House deal; FDA asks Amgen to withdraw Tavneos and, separately, issues Commissioner’s National Priority Vouches to three unnamed psychedelics companies.
Scroll to top